A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.

ABSTRACT: DNA-damaging agents exploit increased genomic instability, a hallmark of cancer. Recently, inhibitors targeting the DNA damage response (DDR) pathways, such as PARP inhibitors, have also shown promising therapeutic potential. However, not all tumors respond well to these treatments, suggesting additional determinants of response are required. Schlafen 11 (SLFN11), a putative DNA/RNA helicase that induces irreversible replication block, is emerging as an important regulator of cellular response to DNA damage. Preclinical and emerging clinical trial data suggest that SLFN11 is a predictive biomarker of response to a wide range of therapeutics that cause DNA damage including platinum salts and topoisomerase I/II inhibitors, as well as PARP inhibitors, which has raised exciting possibilities f

SUBMITTER: Zhang B 

PROVIDER: S-EPMC8576031 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature